OKYO Pharma

OKYO Pharma initiates Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), with the first subject dosed. OK-101, a lipid-conjugated chemerin peptide agonist, targets the chemerin receptor on eye immune cells, aiming to address NCP, a condition currently without FDA-approved treatments. The trial, led by Pedram Hamrah of Tufts Medical Center, will enrol 48 patients diagnosed with NCP via confocal microscopy.

OKYO Pharma's Phase 2 trial of topical OK-101 for neuropathic corneal pain (NCP) has dosed its first patient. The double-masked, randomized, 12-week placebo-controlled study aims to enroll 48 patients with NCP confirmed via confocal microscopy. OK-101, a non-opioid therapeutic, targets severe pain from corneal nerve damage, currently lacking FDA-approved treatments. Preclinical studies showed OK-101's anti-inflammatory and pain-relieving effects, with a lipid anchor prolonging its ocular residence time. The trial is led by Dr. Pedram Hamrah at Tufts Medical Center, focusing on advancing ocular pain research and treatment.

OKYO Pharma Ltd announced the start of patient screening and recruitment for a Phase 2 trial of OK-101 for neuropathic corneal pain. The double-masked, randomized, placebo-controlled trial aims to enroll 48 patients and evaluate OK-101's efficacy using the Visual Analog Scale. The company also secured a U.S. patent for OK-101 and saw increased ownership by Executive Chairman Gabriele Cerrone. Despite financial challenges, including a negative gross profit and operating income, analysts maintain a Buy rating for OKYO Pharma.

OKYO Pharma initiates Phase 2 trial of OK-101 for neuropathic corneal pain (NCP), a condition without FDA-approved treatments. The trial is a double-masked, randomized, placebo-controlled study enrolling 48 patients, with pain relief measured via Visual Analog Scale (VAS).